gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin cost effect spinraza
highlight week decemb decemb non-profit institut clinic econom review
icer releas draft evid report assess cost-effect spinraza unrat
zolgensma formerli avexi novarti compani nr treatment spinal muscular atrophi
sma draft report deem zolgensma would cost-effect per qali spinraza
per qali set model zolgensma placehold price mm million placehold price use
icer calcul compar million rang cost effect novarti suggest previous krystal
buy announc complet dose patient phase ii studi hsv-base gene
therapi gt dystroph epidermolysi bullosa deb compani select pivot trial endpoint base
result studi anticip bla file possibl sangamo therapeut
unrat announc dose patient phase i/ii trial zinc finger nuclease-bas
vivo gene edit ge candid sb-fix hemophilia compani present indic trial
activ site us eu respect earli result expect crispr ge stock
friday announc buy cfo andrew hack step
march return invest industri
look forward decemb januari happi holiday
weekli price move figur vivo genet medicin aav srna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
januari non-deal roadshow meiragtx san francisco healthcar week ceo cdo ir sf
analyst taylor feehley phd moder kol call featur patent attorney discuss ip issu
microbiom medicin space issu may relev genet medicin buy
analyst gbola amusa md cfa moder panel titl improv cell therapi via gener
technolog summit
buy buy misunderstand misdirect bear decemb
share under-perform nbi week ahead research bear view relay
incorrect inform ip portfolio potenti royalti unrat sarepta gt
candid use consensu model royalti regenxbio product
sought comment manag given factual point bear address
includ contend relev use instead
addit issu patent us eu cover sequenc eu rule regenxbio
favor patent valid defeat intent unknown parti ident claim amend
formal uniqu patent patent unaffect outcom
patent claim maintain aa sequenc ident
buy clinic momentumpii dose piii start bla decemb
announc complet dose patient phase ii trial compani lead
asset hsv-base gt dystroph epidermolysi bullosa deb
pleas refer import disclosur inform regul analyst certif found page report
compani re-affirmed result studi anticip result enabl compani select
endpoint plan pivot trial due start
compani execut guidanc us posit ahead potenti bla file
genet medicin news decemb decemb
gener privat appoint tom graney cfo decemb
neutral partner michael foundat advanc develop new tx pd decemb
unrat dose patient pi/ii trial vivo ge candid sb-fix hem decemb
prqr buy publish previous announc result pi/ii studi decemb
unrat appoint emma reev stephani okey board director decemb
unrat receiv ip eu method creat gene-edit plant decemb
unrat announc ad nasdaq biotech nbi effect decemb
jnci comment cost-effect kymriah relapsed/refractori b-cell decemb
unrat appoint new member execut leadership team decemb
onc unrat publish role elicit tumor respons tx decemb
stoke privat appoint shamim ruff nanci wyant leadership team decemb
unrat receiv orphan drug design lentivir gt fabri diseas decemb
neutral close licens research collabor unrat co decemb
buy complet dose patient studi viral-bas gt deb decemb
mina tx privat enrol patient phase ib trial mtl-cebpa/nexavar combo liver cancer decemb
 center mainz publish pre-peer review mirna mimic thrombosi prevent decemb
precis bioscienc privat appoint shalini sharp board director decemb
roivant scienc privat collabor unrat daiichi sankyo certain dev program decemb
sln gb unrat add sirna target apolipoprotein cardiovascular diseas decemb
tx privat appoint andrew allen md board director decemb
unrat triarm tx privat launch eden biocel non-vir car-t therapi decemb
inscripta privat expand seri mm follow new mm contribut decemb
unrat announc plan transit leadership team effect januari decemb
umrx unrat announc ad nbi effect decemb decemb
unrat receiv orphan drug design bpdcn decemb
cgt catapult collabor phion therapeut rala deliveri technolog decemb
unrat announc ad nbi effect decemb decemb
unrat receiv track design colorect cancer decemb
icer releas draft evid report cost-effect spinraza zolgensma sma decemb
nv nr offer acquir cellforcur enhanc cell gene therapi manufactur decemb
sirnaom privat receiv fda clearanc phase ii trial rnai nmsc decemb
unrat complet submiss nda golodirsen duchenn muscular dystrophi decemb
tng-par unrat announc endpoint met vaccin hpv-posit cancer pt decemb
xon unrat gain develop right car-t therapi unrat merck decemb
unrat announc ad nbi effect decemb decemb
page
bntc unrat report trial recurrent/met hnscc fail meet requir orr decemb
buy announc cfo andrew hack depart effect march decemb
fbio unrat provid recap corpor highlight achiev decemb
onc unrat appoint joon board director decemb
unrat enter mm loan secur agreement solar capit partner decemb
unrat announc ad nbi effect decemb decemb
xon unrat receiv ind clearanc pi/ib trial car-t aml md decemb
compani mention report
page
select catalyst genet medicin coverag
figur ind submiss anticip uniqur krystal
submit cta hypertriglyceridemia
submit ind malign
dcr-hbv submit ind cta hbv
submit ind huntington diseas
submit ind autosom recess congenit ichthyosi
fda/ema regard path registr xlmtm
cobomarsen initi phase ii trial ctcl/nhl
cobomarsen announc interim data least one dlbcl cll
phase i/ii data choroideremia addit
initi phase i/ii studi antitrypsin defici
submit ind applic rett syndrom al
remlarsen announc preclin safeti efficaci lung fibrosi data
data phase ii ist chm
complet ind-en studi pomp diseas asset
page
select catalyst outsid genet medicin coverag
complet phase ia studi mage solid tumor
submit impd leukocyt adhes deficiency-i
initi phase ii/iii trial sanfilippo mp iiia
complet phase ia studi anti-bcma car-t mm
decis registr studi base phase data
submit ind fabri diseas
report interim phase i/ii data gsdia
submit bla r/r aggress b-cell nhl
initi phase trial
report long-term result ind-en studi
initi clinic trial sma use aav-bas gene therapi
initi clinic trial infantil batten diseas
expand phase ib trial r/r cell upenn md anderson
initi pivot phase trial rdeb
figur ultragenyx lysogen data readout anticip
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end decemb vivo gm perform srna ivg
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm nightstar genet rna therapytickerratingccm ptupsideclosechang changemc mm silenc gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp top pick uniqur also chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu tamid
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
